SMC decision expands options for people with chronic itch

Original title: “Livdelzi accepted in Scotland for treatment of PBC”

meaningful improvement thresholds for pruritus and sleep disturbance in pbc using the worst itch and sleep interference numerical rating scales

Original title: “Meaningful Improvement Thresholds for Pruritus and Sleep Disturbance in PBC Using the Worst Itch and Sleep Interference Numerical Rating Scales.”

burden of fatigue or pruritus in patients with primary biliary cholangitis a united states matched case control study

Original title: “Burden of fatigue or pruritus in patients with primary biliary cholangitis: a United States matched case-control study.”

real world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the united states

Original title: “Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United States.”

First IBAT inhibitor for PBC cholestatic pruritus

Original title: “Lynavoy recommended for EU approval by the CHMP”

hepatic enigma pediatric presentation of primary biliary cholangitis

Original title: “A hepatic enigma: Pediatric presentation of primary biliary cholangitis.”

aisf practice guidance on the treatment of primary biliary cholangitis a 2026 update

Original title: “AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update.”

burden of primary biliary cholangitis on the italian national health service retrospective analysis from an administrative database

Original title: “Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative database.”

steatotic liver disease at primary biliary cholangitis diagnosis association with ursodeoxycholic acid response and outcomes

Original title: “Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes.”

easl aasld delphi consensus statement on surrogate endpoints and real world evidence in primary biliary cholangitis

Original title: “EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis.”

can we cure primary biliary cholangitis

Original title: “Can we cure primary biliary cholangitis?”

primary biliary cholangitis current insights and novel therapies

Original title: “Primary biliary cholangitis: current insights and novel therapies.”

dendriform pulmonary ossification in fibrosing interstitial lung disease with primary biliary cholangitis

Original title: “Dendriform pulmonary ossification in fibrosing interstitial lung disease with primary biliary cholangitis.”

seladelpar in patients with primary biliary cholangitis and compensated cirrhosis efficacy and safety from response and assure studies

Original title: “Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.”

fracture risk under selective and non selective ppar agonists in primary biliary cholangitis

Original title: “Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.”

meta analysis ppar agonists for pruritus and quality of life in primary biliary cholangitis

Original title: “Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.”

primary biliary cholangitis and prognostic models reply

Original title: “Primary Biliary Cholangitis and Prognostic Models-Reply.”

bullous pemphigoid and primary biliary cholangitis a rare association with therapeutic challenge

Original title: “[Bullous pemphigoid and primary biliary cholangitis, a rare association with therapeutic challenge].”

optimising primary therapy in primary biliary cholangitis opera protocol for a randomised double blind placebo controlled trial of enhanced primary therapy with obeticholic acid

Original title: “Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.”